P. Vlieghe

发表

Synthetic therapeutic peptides: science and market.

M. Khrestchatisky, Jean Martinez, P. Vlieghe, 2010, Drug discovery today.

The WETwin project: Enhancing the Role of Wetlands in Integrated Water Resources Management for Twinned River Basins in the EU, Africa and South-America in Support of EU Water Initiatives

F. Hattermann, A. Griensven, T. Hein, 2016 .

Medicinal Chemistry Based Approaches and Nanotechnology‐Based Systems to Improve CNS Drug Targeting and Delivery

M. Khrestchatisky, P. Vlieghe, 2013, Medicinal research reviews.

Identification and characterization of highly versatile peptide-vectors that bind non-competitively to the low-density lipoprotein receptor for in vivo targeting and delivery of small molecules and protein cargos

M. Khrestchatisky, P. Vlieghe, M. David, 2018, PloS one.

Colloidal anticancer drugs bioavailabilities in oral administration models.

F. Tosini, J. Delpero, P. Vlieghe, 2003, International journal of pharmaceutics.

New 3'-azido-3'-deoxythymidin-5'-yl O-(4-hydroxyalkyl or -alkenyl or -alkylepoxide) carbonate prodrugs: synthesis and anti-HIV evaluation.

E. De Clercq, C. Pannecouque, J. Kraus, 2001, Journal of medicinal chemistry.

New 3'-azido-3'-deoxythymidin-5'-yl O-(omega-hydroxyalkyl) carbonate prodrugs: synthesis and anti-HIV evaluation.

E. De Clercq, C. Pannecouque, F. Bihel, 2001, Journal of medicinal chemistry.

Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles

F. Zoulim, J. Kraus, C. Borel, 1997, Antimicrobial agents and chemotherapy.

Erratum to “Are 5′-O-Carbamate-2′,3′-dideoxythiacytidine new anti-HIV and anti-HBV nucleoside drugs or prodrugs?”[Bioorg. Med. Chem. Lett. 13 (2003) 2459] ☆

C. Pannecouque, J. Kraus, D. Dormont, 2003 .

Are 5'-O-carbamate-2',3'-dideoxythiacytidine new anti-HIV and anti-HBV nucleoside drugs or prodrugs?

E. De Clercq, C. Pannecouque, J. Kraus, 2003, Bioorganic & medicinal chemistry letters.

Chemical optimization of new ligands of the low-density lipoprotein receptor as potential vectors for central nervous system targeting.

G. Rougon, M. Khrestchatisky, P. Vlieghe, 2012, Journal of medicinal chemistry.

Peptide-based vectors for blood-brain barrier targeting and delivery of drugs to the central nervous system.

M. Khrestchatisky, P. Vlieghe, 2010, Therapeutic delivery.

New bicyclam-AZT conjugates: design, synthesis, anti-HIV evaluation, and their interaction with CXCR-4 coreceptor.

J. Chermann, J. Kraus, P. Vlieghe, 1999, Journal of medicinal chemistry.

Synthesis of new covalently bound kappa-carrageenan-AZT conjugates with improved anti-HIV activities.

Myriam Witvrouw, Christophe Pannecouque, Jean-Louis Kraus, 2002, Journal of medicinal chemistry.

Tri-N-Boc-tetraazamacrocycle-nucleoside conjugates: synthesis and anti-HIV activities.

J. Chermann, J. Kraus, G. Quéléver, 1998, Nucleosides & nucleotides.

Tri‐N‐Boc‐tetraazamacrocycle—Nucleoside Conjugates: Synthesis and Anti‐HIV Activities.

J. Chermann, J. Kraus, G. Quéléver, 2010 .

Synthetic therapeutic peptides: science and market.

M. Khrestchatisky, Jean Martinez, P. Vlieghe, 2010, Drug discovery today.

Chemical optimization of new ligands of the low-density lipoprotein receptor as potential vectors for central nervous system targeting.

G. Rougon, M. Khrestchatisky, P. Vlieghe, 2012, Journal of medicinal chemistry.